Health
### UK Government Replaces Firm Assessing COVID Vaccine Harm Claims Amid £48 Million Cost Spiral
**LONDON, UK** – The UK government has taken the decisive step of replacing the firm responsible for assessing claims related to harm from COVID-19 vaccines, Crawford & Company Adjusters, after the costs for their services ballooned to an astonishing £48 million. This figure represents an eight-fold increase from the original estimate for the critical work.
The contract with Crawford & Company Adjusters was part of the UK’s Vaccine Damage Payment Scheme (VDPS), which provides a one-off tax-free payment to individuals who can demonstrate severe disablement caused by a vaccine. Established in 1979, the VDPS has seen a significant surge in claims following the widespread COVID-19 vaccination program, putting unprecedented pressure on its administrative processes.
The reported £48 million paid to Crawford & Company starkly contrasts with the initial estimated cost of approximately £6 million, highlighting a substantial miscalculation or unforeseen complexities in the assessment process. This significant overrun raises questions about financial oversight and the management of public funds allocated to the scheme.
The firm’s role involved evaluating the merits of each claim, a crucial step in determining eligibility for compensation under the VDPS. The escalating costs have prompted concerns regarding the efficiency and cost-effectiveness of this outsourced service.
While the specific replacement firm has not yet been publicly identified, the move aims to bring costs under control and potentially streamline the assessment process. The decision underscores the government’s commitment to ensuring the efficient and fiscally responsible operation of the VDPS. However, the transition may also raise concerns among claimants awaiting assessment, who have often faced lengthy delays in processing their applications.
A spokesperson for the Department of Health and Social Care (DHSC), which oversees the VDPS, acknowledged the necessity of the change, stating, “We are committed to supporting individuals severely impacted by vaccines and ensuring the Vaccine Damage Payment Scheme operates with maximum efficiency and value for taxpayer money. The replacement of the assessment firm reflects our ongoing efforts to manage costs responsibly while maintaining the integrity and fairness of the scheme.”
The escalating costs associated with assessing vaccine harm claims present a significant challenge for the VDPS, a scheme crucial for public confidence in vaccination programs. The government’s decision to replace the contracted firm signals a renewed focus on fiscal prudence and operational effectiveness as it navigates the ongoing responsibilities of the scheme.
